Sangamo Therapeutics, Inc. (SGMO)
USD 0.65
(4.74%)
USD 0.65
(4.74%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 82.43 Million USD | -69.19% |
| 2022 | 267.55 Million USD | -22.8% |
| 2021 | 346.58 Million USD | -21.44% |
| 2020 | 441.18 Million USD | 115.45% |
| 2019 | 204.77 Million USD | -8.53% |
| 2018 | 223.87 Million USD | 126.5% |
| 2017 | 98.84 Million USD | 355.57% |
| 2016 | 21.69 Million USD | -12.5% |
| 2015 | 24.79 Million USD | -32.21% |
| 2014 | 36.57 Million USD | 91.23% |
| 2013 | 19.12 Million USD | 8.45% |
| 2012 | 17.63 Million USD | 144.82% |
| 2011 | 7.2 Million USD | 1.58% |
| 2010 | 7.09 Million USD | -54.7% |
| 2009 | 15.65 Million USD | 25.72% |
| 2008 | 12.45 Million USD | 5.74% |
| 2007 | 11.77 Million USD | 66.47% |
| 2006 | 7.07 Million USD | -36.66% |
| 2005 | 11.16 Million USD | 375.68% |
| 2004 | 2.34 Million USD | 49.46% |
| 2003 | 1.57 Million USD | -20.7% |
| 2002 | 1.98 Million USD | -25.75% |
| 2001 | 2.66 Million USD | 31.11% |
| 2000 | 2.03 Million USD | 56.54% |
| 1999 | 1.3 Million USD | 107.01% |
| 1998 | 628 Thousand USD | 28.95% |
| 1997 | 487 Thousand USD | 363.81% |
| 1996 | 105 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 69.32 Million USD | -4.07% |
| 2024 Q1 | 72.26 Million USD | -12.34% |
| 2023 Q2 | 91.43 Million USD | -12.89% |
| 2023 Q4 | 82.43 Million USD | -2.76% |
| 2023 FY | 82.43 Million USD | -69.19% |
| 2023 Q3 | 84.77 Million USD | -7.28% |
| 2023 Q1 | 104.95 Million USD | -60.77% |
| 2022 FY | 267.55 Million USD | -22.8% |
| 2022 Q2 | 298.84 Million USD | -6.55% |
| 2022 Q1 | 319.78 Million USD | -7.73% |
| 2022 Q3 | 284.75 Million USD | -4.71% |
| 2022 Q4 | 267.55 Million USD | -6.04% |
| 2021 FY | 346.58 Million USD | -21.44% |
| 2021 Q2 | 389.9 Million USD | -4.36% |
| 2021 Q3 | 366.38 Million USD | -6.03% |
| 2021 Q4 | 346.58 Million USD | -5.4% |
| 2021 Q1 | 407.67 Million USD | -7.59% |
| 2020 FY | 441.18 Million USD | 115.45% |
| 2020 Q2 | 383.45 Million USD | 101.97% |
| 2020 Q1 | 189.86 Million USD | -7.28% |
| 2020 Q4 | 441.18 Million USD | -0.37% |
| 2020 Q3 | 442.82 Million USD | 15.48% |
| 2019 Q2 | 227.73 Million USD | 6.64% |
| 2019 FY | 204.77 Million USD | -8.53% |
| 2019 Q3 | 220.89 Million USD | -3.0% |
| 2019 Q4 | 204.77 Million USD | -7.3% |
| 2019 Q1 | 213.54 Million USD | -4.61% |
| 2018 Q3 | 226.69 Million USD | -5.49% |
| 2018 Q1 | 98.8 Million USD | -0.04% |
| 2018 Q2 | 239.86 Million USD | 142.77% |
| 2018 FY | 223.87 Million USD | 126.5% |
| 2018 Q4 | 223.87 Million USD | -1.24% |
| 2017 Q3 | 83.13 Million USD | -6.54% |
| 2017 FY | 98.84 Million USD | 355.57% |
| 2017 Q4 | 98.84 Million USD | 18.89% |
| 2017 Q2 | 88.95 Million USD | 321.04% |
| 2017 Q1 | 21.12 Million USD | -2.62% |
| 2016 FY | 21.69 Million USD | -12.5% |
| 2016 Q3 | 21.14 Million USD | 1.24% |
| 2016 Q4 | 21.69 Million USD | 2.62% |
| 2016 Q2 | 20.88 Million USD | 18.38% |
| 2016 Q1 | 17.64 Million USD | -28.86% |
| 2015 Q4 | 24.79 Million USD | -14.37% |
| 2015 FY | 24.79 Million USD | -32.21% |
| 2015 Q2 | 30 Million USD | -3.27% |
| 2015 Q1 | 31.01 Million USD | -15.21% |
| 2015 Q3 | 28.95 Million USD | -3.49% |
| 2014 FY | 36.57 Million USD | 91.23% |
| 2014 Q4 | 36.57 Million USD | -1.69% |
| 2014 Q2 | 36.48 Million USD | -4.19% |
| 2014 Q1 | 38.07 Million USD | 99.05% |
| 2014 Q3 | 37.2 Million USD | 2.0% |
| 2013 FY | 19.12 Million USD | 8.45% |
| 2013 Q1 | 14.25 Million USD | -19.16% |
| 2013 Q2 | 14.81 Million USD | 3.93% |
| 2013 Q3 | 14.22 Million USD | -4.0% |
| 2013 Q4 | 19.12 Million USD | 34.47% |
| 2012 Q1 | 16.08 Million USD | 123.26% |
| 2012 Q3 | 15.41 Million USD | -4.18% |
| 2012 Q2 | 16.08 Million USD | -0.01% |
| 2012 FY | 17.63 Million USD | 144.82% |
| 2012 Q4 | 17.63 Million USD | 14.44% |
| 2011 FY | 7.2 Million USD | 1.58% |
| 2011 Q2 | 4 Million USD | 18.68% |
| 2011 Q1 | 3.37 Million USD | -52.37% |
| 2011 Q3 | 4.14 Million USD | 3.37% |
| 2011 Q4 | 7.2 Million USD | 73.84% |
| 2010 FY | 7.09 Million USD | -54.7% |
| 2010 Q2 | 3.63 Million USD | -61.06% |
| 2010 Q1 | 9.34 Million USD | -40.34% |
| 2010 Q4 | 7.09 Million USD | 66.87% |
| 2010 Q3 | 4.25 Million USD | 16.85% |
| 2009 Q1 | 10.88 Million USD | -12.58% |
| 2009 FY | 15.65 Million USD | 25.72% |
| 2009 Q3 | 6.93 Million USD | -10.68% |
| 2009 Q4 | 15.65 Million USD | 125.83% |
| 2009 Q2 | 7.76 Million USD | -28.7% |
| 2008 FY | 12.45 Million USD | 5.74% |
| 2008 Q2 | 15.32 Million USD | 48.96% |
| 2008 Q3 | 14.72 Million USD | -3.87% |
| 2008 Q4 | 12.45 Million USD | -15.44% |
| 2008 Q1 | 10.28 Million USD | -12.68% |
| 2007 Q4 | 11.77 Million USD | 11.96% |
| 2007 Q1 | 6.59 Million USD | -6.83% |
| 2007 FY | 11.77 Million USD | 66.47% |
| 2007 Q3 | 10.52 Million USD | 50.24% |
| 2007 Q2 | 7 Million USD | 6.22% |
| 2006 FY | 7.07 Million USD | -36.66% |
| 2006 Q3 | 7.36 Million USD | -3.9% |
| 2006 Q4 | 7.07 Million USD | -3.92% |
| 2006 Q2 | 7.66 Million USD | -9.58% |
| 2006 Q1 | 8.47 Million USD | -24.12% |
| 2005 Q4 | 11.16 Million USD | 406.53% |
| 2005 Q1 | 1.76 Million USD | -24.87% |
| 2005 Q2 | 1.41 Million USD | -19.73% |
| 2005 Q3 | 2.2 Million USD | 55.72% |
| 2005 FY | 11.16 Million USD | 375.68% |
| 2004 Q2 | 1.04 Million USD | 13.99% |
| 2004 Q1 | 915 Thousand USD | -41.76% |
| 2004 FY | 2.34 Million USD | 49.46% |
| 2004 Q4 | 2.34 Million USD | 69.04% |
| 2004 Q3 | 1.38 Million USD | 33.17% |
| 2003 Q4 | 1.57 Million USD | -27.37% |
| 2003 Q3 | 2.16 Million USD | 24.67% |
| 2003 Q1 | 1.27 Million USD | -35.44% |
| 2003 FY | 1.57 Million USD | -20.7% |
| 2003 Q2 | 1.73 Million USD | 35.65% |
| 2002 Q1 | 2.03 Million USD | -23.88% |
| 2002 Q4 | 1.98 Million USD | 35.13% |
| 2002 Q3 | 1.46 Million USD | -5.54% |
| 2002 FY | 1.98 Million USD | -25.75% |
| 2002 Q2 | 1.55 Million USD | -23.58% |
| 2001 Q2 | 1.13 Million USD | -45.75% |
| 2001 FY | 2.66 Million USD | 31.11% |
| 2001 Q4 | 2.66 Million USD | 8.1% |
| 2001 Q1 | 2.08 Million USD | 2.36% |
| 2001 Q3 | 2.46 Million USD | 118.41% |
| 2000 Q3 | 921 Thousand USD | -14.48% |
| 2000 Q4 | 2.03 Million USD | 120.96% |
| 2000 Q1 | 14.09 Million USD | 0.0% |
| 2000 FY | 2.03 Million USD | 56.54% |
| 2000 Q2 | 1.07 Million USD | -92.36% |
| 1999 FY | 1.3 Million USD | 107.01% |
| 1998 FY | 628 Thousand USD | 28.95% |
| 1997 FY | 487 Thousand USD | 363.81% |
| 1996 FY | 105 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 75.45% |
| Alkermes plc | 933.53 Million USD | 91.17% |
| Agenus Inc. | 462.29 Million USD | 82.169% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 97.965% |
| Aptorum Group Limited | 5.25 Million USD | -1468.14% |
| Ardelyx, Inc. | 130.76 Million USD | 36.96% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 82.769% |
| Bicycle Therapeutics plc | 224.41 Million USD | 63.267% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | 36.692% |
| ChromaDex Corporation | 26.5 Million USD | -210.974% |
| Chimerix, Inc. | 19.74 Million USD | -317.488% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -134.337% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -13.596% |
| CRISPR Therapeutics AG | 346.76 Million USD | 76.228% |
| Precision BioSciences, Inc. | 140.92 Million USD | 41.504% |
| Dyadic International, Inc. | 2.34 Million USD | -3421.798% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -406.875% |
| Fortress Biotech, Inc. | 165.93 Million USD | 50.323% |
| Lantern Pharma Inc. | 2.73 Million USD | -2908.853% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -15.323% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -2236.056% |
| Incyte Corporation | 1.59 Billion USD | 94.823% |
| IO Biotech, Inc. | 17.55 Million USD | -369.543% |
| Jaguar Health, Inc. | 45.86 Million USD | -79.726% |
| Novavax, Inc. | 2.57 Billion USD | 96.795% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -128.612% |
| Opthea Limited | 264.6 Million USD | 68.846% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | 36.933% |
| ContextLogic Inc. | 206 Million USD | 59.984% |
| MiMedx Group, Inc. | 96.33 Million USD | 14.426% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -71.657% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -2235.949% |
| NextCure, Inc. | 14.99 Million USD | -449.663% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -1939.411% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -1134.581% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -76.369% |
| Vaxcyte, Inc. | 167.44 Million USD | 50.771% |
| PDS Biotechnology Corporation | 33.25 Million USD | -147.851% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 64.954% |
| Pharming Group N.V. | 244.07 Million USD | 66.226% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -591.436% |
| Avidity Biosciences, Inc. | 127.79 Million USD | 35.494% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -1147.609% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -1147.609% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -1140.9% |
| Acelyrin, Inc. | 86.35 Million USD | 4.54% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -6244.704% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -473.287% |
| Summit Therapeutics Inc. | 125.25 Million USD | 34.189% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -769.638% |
| Senti Biosciences, Inc. | 52.57 Million USD | -56.803% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -19.855% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 45.593% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -4114.366% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -6072.149% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 63.659% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -780.036% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 63.757% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 83.33% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -655.296% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -199.637% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -581.0% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 83.059% |
| Immix Biopharma, Inc. | 3.72 Million USD | -2114.879% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -118.008% |
| MEI Pharma, Inc. | 8.35 Million USD | -886.631% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -184.105% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 76.284% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 43.488% |
| Fortress Biotech, Inc. | 165.93 Million USD | 50.323% |
| Precigen, Inc. | 41.64 Million USD | -97.947% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -65.097% |
| AlloVir, Inc. | 45.01 Million USD | -83.123% |
| C4 Therapeutics, Inc. | 130.33 Million USD | 36.754% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 40.179% |
| ImmuCell Corporation | 18.81 Million USD | -338.123% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -192.046% |
| Onconetix, Inc. | 23.18 Million USD | -255.608% |
| PureTech Health plc | 125.58 Million USD | 34.36% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -821.039% |
| Elevation Oncology, Inc. | 34.28 Million USD | -140.456% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -3271.493% |
| Seer, Inc. | 39.36 Million USD | -109.407% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -33.313% |
| Innoviva, Inc. | 568.55 Million USD | 85.501% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -202.751% |
| ESSA Pharma Inc. | 3.49 Million USD | -2258.55% |
| GlycoMimetics, Inc. | 6.9 Million USD | -1094.322% |
| GT Biopharma, Inc. | 6.63 Million USD | -1142.771% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 68.821% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 69.726% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | 1.896% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -743.391% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -203.408% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -2455.45% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -11.748% |
| Aptose Biosciences Inc. | 15.8 Million USD | -421.441% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -646.697% |
| Soligenix, Inc. | 7.27 Million USD | -1033.115% |
| Century Therapeutics, Inc. | 175.94 Million USD | 53.147% |
| Kura Oncology, Inc. | 51.66 Million USD | -59.562% |
| TScan Therapeutics, Inc. | 121.28 Million USD | 32.032% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -1894.508% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -1146.368% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 67.366% |
| Autolus Therapeutics plc | 263.9 Million USD | 68.764% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -686.424% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | 7.234% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -75.767% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 76.638% |
| GRI Bio, Inc. | 2.69 Million USD | -2956.47% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -10082.13% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -165.135% |
| IGM Biosciences, Inc. | 220.17 Million USD | 62.561% |
| INmune Bio, Inc. | 18.86 Million USD | -337.032% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 67.86% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -209.412% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -2932.402% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -2412.997% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -41.02% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | 14.274% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 68.862% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 89.984% |
| Verastem, Inc. | 71.18 Million USD | -15.801% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -67.629% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -113.679% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -68.464% |
| Histogen Inc. | 5.69 Million USD | -1346.955% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -1779.627% |
| Surrozen, Inc. | 8.14 Million USD | -912.069% |
| Organovo Holdings, Inc. | 2.74 Million USD | -2899.745% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -26164.425% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -46.6% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -399.231% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -61.308% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -9869.221% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | 34.951% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -662.309% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 45.368% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -3061.569% |
| Apollomics, Inc. | 14.15 Million USD | -482.442% |
| Amarin Corporation plc | 279.58 Million USD | 70.516% |
| Mesoblast Limited | 188.79 Million USD | 56.338% |
| Turnstone Biologics Corp. | 14.14 Million USD | -482.648% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 54.404% |
| Synaptogenix, Inc. | 5.52 Million USD | -1390.794% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -1139.967% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 51.541% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -863.318% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -4590.641% |
| Exelixis, Inc. | 678.44 Million USD | 87.85% |
| Better Therapeutics, Inc. | 23.84 Million USD | -245.747% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 49.75% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 86.127% |
| NLS Pharmaceutics AG | 10.68 Million USD | -671.83% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -4977.124% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -111.763% |
| Gritstone bio, Inc. | 125.91 Million USD | 34.535% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -461.686% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -1519.946% |
| Avid Bioservices, Inc. | 275.66 Million USD | 70.097% |
| Insmed Incorporated | 1.66 Billion USD | 95.039% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -971.39% |
| MediWound Ltd. | 27.18 Million USD | -203.207% |
| OmniAb, Inc. | 87.4 Million USD | 5.683% |
| Alector, Inc. | 487.66 Million USD | 83.097% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 79.568% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -347.398% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -114.82% |
| Zai Lab Limited | 240.17 Million USD | 65.678% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 86.917% |
| Aura Biosciences, Inc. | 29.22 Million USD | -182.044% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | 13.299% |
| Immunic, Inc. | 25.36 Million USD | -224.949% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -19.061% |
| Veracyte, Inc. | 93.71 Million USD | 12.042% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -3050.298% |
| FibroGen, Inc. | 585.72 Million USD | 85.926% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -374.216% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -12522.268% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -1357.583% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 98.923% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -905.526% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | 1.891% |
| TG Therapeutics, Inc. | 169.08 Million USD | 51.248% |
| Galecto, Inc. | 5.89 Million USD | -1298.117% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -895.087% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 96.852% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -186.007% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -553.142% |
| XBiotech Inc. | 8.39 Million USD | -881.696% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -461.686% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -55.008% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 77.298% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -206.625% |
| Theravance Biopharma, Inc. | 169 Million USD | 51.224% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 93.219% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 83.527% |
| Vaxxinity, Inc. | 30.94 Million USD | -166.394% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 91.523% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -1266.797% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 88.939% |
| NexImmune, Inc. | 5.08 Million USD | -1521.346% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -22095.566% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -2580.88% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 98.84% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -1499.389% |
| Scopus BioPharma Inc. | 7.45 Million USD | -1005.825% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -213.505% |
| Ainos, Inc. | 7.39 Million USD | -1014.83% |
| Pluri Inc. | 34.11 Million USD | -141.654% |
| Prothena Corporation plc | 135.01 Million USD | 38.946% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 66.091% |
| Celularity Inc. | 102.92 Million USD | 19.913% |
| Rallybio Corporation | 9.43 Million USD | -773.601% |
| Cue Biopharma, Inc. | 24.44 Million USD | -237.218% |
| MeiraGTx Holdings plc | 319.99 Million USD | 74.239% |
| Omeros Corporation | 403.25 Million USD | 79.558% |
| Humacyte, Inc. | 114.67 Million USD | 28.117% |
| Immunocore Holdings plc | 228.15 Million USD | 63.87% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -1590.933% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -7.419% |
| Blueprint Medicines Corporation | 918.64 Million USD | 91.027% |
| CalciMedica, Inc. | 4.02 Million USD | -1946.5% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -372.341% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 46.522% |
| Scholar Rock Holding Corporation | 85.81 Million USD | 3.943% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 70.326% |
| Pulmatrix, Inc. | 15.96 Million USD | -416.4% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -422.621% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -235.012% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 67.133% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -62.314% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 93.191% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -159.362% |
| Nutriband Inc. | 1.07 Million USD | -7540.333% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -675.256% |
| Vor Biopharma Inc. | 59.1 Million USD | -39.471% |
| Roivant Sciences Ltd. | 773.95 Million USD | 89.349% |
| Evogene Ltd. | 17.99 Million USD | -358.216% |
| ProKidney Corp. | 29.21 Million USD | -182.15% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -14.524% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -11592.906% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 95.636% |
| CorMedix Inc. | 11.91 Million USD | -591.695% |
| BioLineRx Ltd. | 50.7 Million USD | -62.583% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 44.846% |
| Galectin Therapeutics Inc. | 88.44 Million USD | 6.793% |
| Atai Life Sciences N.V. | 49.16 Million USD | -67.676% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -164.613% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -358.93% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | 33.861% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -1357.959% |
| MediciNova, Inc. | 3.89 Million USD | -2018.255% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -350.971% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -5380.039% |
| GeoVax Labs, Inc. | 3.51 Million USD | -2241.926% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 79.25% |
| Biomea Fusion, Inc. | 30.69 Million USD | -168.599% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 96.971% |
| Mereo BioPharma Group plc | 15.96 Million USD | -416.433% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -164.2% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -40.469% |
| Absci Corporation | 58.3 Million USD | -41.385% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -332.765% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -157.105% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -11.713% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | 5.773% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -144.101% |
| Allakos Inc. | 74.79 Million USD | -10.215% |
| Imunon, Inc. | 8.53 Million USD | -866.341% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -266.353% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 28.202% |
| BioAtla, Inc. | 48.98 Million USD | -68.279% |
| NLS Pharmaceutics AG | 10.68 Million USD | -671.83% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -2866.283% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | 36.883% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -479.902% |
| XOMA Corporation | 145.58 Million USD | 43.376% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -144.863% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -19.887% |
| aTyr Pharma, Inc. | 31.59 Million USD | -160.889% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -33.337% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -83.327% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -70.309% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -2772.23% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -910.454% |
| Akari Therapeutics, Plc | 4.58 Million USD | -1698.277% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -364.853% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 95.002% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -20308.855% |
| UroGen Pharma Ltd. | 243.52 Million USD | 66.15% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 74.327% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -2885.018% |
| Orgenesis Inc. | 35.53 Million USD | -131.977% |
| Entera Bio Ltd. | 1.37 Million USD | -5877.737% |
| GH Research PLC | 6.7 Million USD | -1130.16% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -1112.25% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -337.868% |
| Xencor, Inc. | 283.55 Million USD | 70.929% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -2660.95% |
| Replimune Group, Inc. | 113.21 Million USD | 27.188% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -2094.045% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | 20.378% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -20308.855% |
| Portage Biotech Inc. | 4.45 Million USD | -1752.427% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -5380.039% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -257.627% |
| OncoCyte Corporation | 49.29 Million USD | -67.214% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -1892.673% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -10236.634% |
| Purple Biotech Ltd. | 10 Million USD | -723.918% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -1324.698% |
| scPharmaceuticals Inc. | 57.26 Million USD | -43.96% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -565.425% |
| HilleVax, Inc. | 78.9 Million USD | -4.466% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -1532.337% |
| Tharimmune, Inc. | 1.81 Million USD | -4441.648% |
| Genprex, Inc. | 3.25 Million USD | -2433.12% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -203.968% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -1474.351% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -39916.019% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -22890.785% |
| OKYO Pharma Limited | 7.42 Million USD | -1010.83% |
| Savara Inc. | 37.19 Million USD | -121.642% |
| Curis, Inc. | 57.61 Million USD | -43.083% |
| Daré Bioscience, Inc. | 26.32 Million USD | -213.078% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -110.289% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -5608.657% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -295.951% |
| BeiGene, Ltd. | 2.23 Billion USD | 96.31% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -287.195% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 68.585% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -287.482% |
| Erasca, Inc. | 78.61 Million USD | -4.862% |
| bluebird bio, Inc. | 424.62 Million USD | 80.587% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -12480.351% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 95.639% |
| DBV Technologies S.A. | 42.8 Million USD | -92.6% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -12480.351% |
| Moderna, Inc. | 4.57 Billion USD | 98.197% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -1078.456% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -4877.838% |
| Molecular Templates, Inc. | 31.17 Million USD | -164.454% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -382.912% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 85.983% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | 33.791% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -200.445% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -126.116% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -48.168% |
| MacroGenics, Inc. | 154.2 Million USD | 46.544% |
| RenovoRx, Inc. | 4.46 Million USD | -1745.79% |
| Adicet Bio, Inc. | 37.12 Million USD | -122.072% |
| Prime Medicine, Inc. | 60.78 Million USD | -35.625% |
| Aditxt, Inc. | 28.53 Million USD | -188.919% |
| Adagene Inc. | 45.16 Million USD | -82.498% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -45518.453% |
| Quantum-Si incorporated | 26.63 Million USD | -209.538% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 88.183% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -2609.439% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | 28.295% |
| SciSparc Ltd. | 1.59 Million USD | -5068.213% |
| Vericel Corporation | 127.7 Million USD | 35.45% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -1381.304% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | 3.427% |
| Generation Bio Co. | 171.63 Million USD | 51.971% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -613.706% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -97.062% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 67.379% |
| Invivyd, Inc. | 51.71 Million USD | -59.405% |
| Relay Therapeutics, Inc. | 91.97 Million USD | 10.377% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -1167.176% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -9.189% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -7973.751% |
| 2seventy bio, Inc. | 310.12 Million USD | 73.42% |
| ADMA Biologics, Inc. | 193.97 Million USD | 57.504% |
| Clene Inc. | 38.95 Million USD | -111.633% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -128.139% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 67.922% |
| GeoVax Labs, Inc. | 3.51 Million USD | -2241.926% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 56.674% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -576.809% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 58.435% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -575.968% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -71.339% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -56.002% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 77.712% |
| Evaxion Biotech A/S | 17.61 Million USD | -367.905% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 48.777% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 46.188% |
| Trevena, Inc. | 48.26 Million USD | -70.803% |
| Surrozen, Inc. | 8.14 Million USD | -912.069% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -281.723% |
| Cingulate Inc. | 10.36 Million USD | -695.619% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -2897.564% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -121.047% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -2198.412% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -526.867% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 74.012% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -231.736% |
| Clearmind Medicine Inc. | 3.61 Million USD | -2183.458% |
| Kronos Bio, Inc. | 54.2 Million USD | -52.088% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -75.229% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -262.188% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -310.707% |
| Statera Biopharma, Inc. | 22.67 Million USD | -263.518% |
| ImmunityBio, Inc. | 1.09 Billion USD | 92.44% |
| Korro Bio, Inc. | 51.75 Million USD | -59.285% |
| Kineta, Inc. | 7.22 Million USD | -1041.415% |
| BioVie Inc. | 9.7 Million USD | -749.638% |
| Codexis, Inc. | 49.94 Million USD | -65.044% |
| Celularity Inc. | 102.92 Million USD | 19.913% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | 14.353% |
| Celcuity Inc. | 51.45 Million USD | -60.219% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -23780.195% |
| Cibus, Inc. | 206.11 Million USD | 60.007% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -94.074% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -212.969% |
| IN8bio, Inc. | 8.77 Million USD | -839.729% |
| Kodiak Sciences Inc. | 213.59 Million USD | 61.406% |
| Annexon, Inc. | 47.11 Million USD | -74.95% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | 7.938% |
| Assembly Biosciences, Inc. | 96.37 Million USD | 14.464% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -502.184% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 96.834% |
| Eyenovia, Inc. | 19.78 Million USD | -316.743% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 53.45% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -973.207% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -242.06% |
| Arcellx, Inc. | 339.75 Million USD | 75.737% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -592.831% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 66.428% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -761.999% |
| Moolec Science SA | 13.94 Million USD | -491.114% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -91.029% |
| Geron Corporation | 146.12 Million USD | 43.588% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -63.13% |
| Royalty Pharma plc | 6.29 Billion USD | 98.691% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -107.243% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -27899.769% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -3250.551% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 56.421% |
| Humacyte, Inc. | 114.67 Million USD | 28.117% |
| Structure Therapeutics Inc. | 29.05 Million USD | -183.753% |
| 89bio, Inc. | 59.96 Million USD | -37.473% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -211.503% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -6792.391% |
| Genelux Corporation | 8.42 Million USD | -879.014% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -1102.348% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | 39.529% |
| Notable Labs, Ltd. | 4.42 Million USD | -1762.051% |
| Liquidia Corporation | 73.13 Million USD | -12.709% |
| Mustang Bio, Inc. | 17.61 Million USD | -367.864% |
| Immunovant, Inc. | 48.95 Million USD | -68.385% |
| Quantum-Si incorporated | 26.63 Million USD | -209.538% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -114.764% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -2556.558% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -11.606% |
| Acasti Pharma Inc. | 11.55 Million USD | -613.273% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -264.623% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -2932.402% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -123.535% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -5948.61% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -1252.247% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -231.923% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -255.56% |
| PepGen Inc. | 34.63 Million USD | -138.032% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -578.796% |
| United Therapeutics Corporation | 1.18 Billion USD | 93.027% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -1080.312% |
| Solid Biosciences Inc. | 38.45 Million USD | -114.346% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -863.318% |
| Immuneering Corporation | 12 Million USD | -586.464% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -26164.425% |
| Silo Pharma, Inc. | 1.56 Million USD | -5152.952% |
| Belite Bio, Inc | 4.21 Million USD | -1857.564% |
| XOMA Corporation | 145.58 Million USD | 43.376% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -3295.099% |
| Bionomics Limited | 10.15 Million USD | -711.451% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -283.57% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -259.765% |
| uniQure N.V. | 624.01 Million USD | 86.79% |
| Cassava Sciences, Inc. | 14.19 Million USD | -480.719% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -45518.453% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 51.562% |
| Forte Biosciences, Inc. | 3.66 Million USD | -2148.582% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -31534.067% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -1121.773% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -973.207% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -374.216% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -680.025% |
| Altimmune, Inc. | 16.54 Million USD | -398.356% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 86.655% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -259.765% |
| Compugen Ltd. | 55.77 Million USD | -47.796% |
| Peak Bio, Inc. | 20.75 Million USD | -297.203% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | 25.375% |
| Benitec Biopharma Inc. | 4.96 Million USD | -1561.286% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 47.775% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -9.656% |
| Zura Bio Limited | 21.29 Million USD | -287.155% |
| PolyPid Ltd. | 17.46 Million USD | -371.909% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | 26.66% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -9.656% |
| Instil Bio, Inc. | 99.8 Million USD | 17.403% |
| argenx SE | 444.95 Million USD | 81.474% |
| Immunome, Inc. | 28.65 Million USD | -187.644% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -888.761% |
| Verona Pharma plc | 58.84 Million USD | -40.094% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -469.564% |
| Shattuck Labs, Inc. | 14.85 Million USD | -454.768% |
| CervoMed Inc. | 2.59 Million USD | -3075.695% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -1591.28% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -547.244% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -682.468% |
| Moolec Science SA | 13.94 Million USD | -491.114% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -3417.511% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -48.273% |
| AnaptysBio, Inc. | 364.28 Million USD | 77.371% |
| Design Therapeutics, Inc. | 11.95 Million USD | -589.47% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -549.898% |
| NeurAxis, Inc. | 1.91 Million USD | -4209.684% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -111.758% |
| Lumos Pharma, Inc. | 13.33 Million USD | -518.263% |
| Achilles Therapeutics plc | 19.08 Million USD | -331.88% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -469.564% |
| 180 Life Sciences Corp. | 5.38 Million USD | -1430.162% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -249.47% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -262.188% |
| Nutriband Inc. | 1.07 Million USD | -7540.333% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -169.406% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -468.072% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 79.457% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -153.851% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -531.714% |
| Palisade Bio, Inc. | 2.73 Million USD | -2909.602% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -1469.256% |
| Beam Therapeutics Inc. | 478.38 Million USD | 82.768% |
| Neurogene Inc. | 36.54 Million USD | -125.541% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 79.286% |
| AEON Biopharma, Inc. | 159.88 Million USD | 48.444% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -72.997% |
| Sesen Bio, Inc. | 30.98 Million USD | -166.05% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -217.526% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -984.329% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 57.886% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 57.079% |
| Athira Pharma, Inc. | 30.05 Million USD | -174.256% |
| Vaccinex, Inc. | 5.94 Million USD | -1287.294% |
| HCW Biologics Inc. | 15.05 Million USD | -447.657% |
| XOMA Corporation | 145.58 Million USD | 43.376% |
| Nektar Therapeutics | 267.04 Million USD | 69.132% |
| Arvinas, Inc. | 644.6 Million USD | 87.212% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -364.853% |
| Merus N.V. | 102.15 Million USD | 19.303% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 43.674% |
| Quince Therapeutics, Inc. | 95.12 Million USD | 13.338% |
| Rezolute, Inc. | 11.73 Million USD | -602.514% |
| Clene Inc. | 38.95 Million USD | -111.633% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -2795.047% |
| BeyondSpring Inc. | 48.26 Million USD | -70.778% |
| Synlogic, Inc. | 32.89 Million USD | -150.594% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -464.107% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -4944.859% |
| Peak Bio, Inc. | 20.75 Million USD | -297.203% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -29.9% |
| Krystal Biotech, Inc. | 39.71 Million USD | -107.567% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 78.114% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | 17.21% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -18949.699% |
| MannKind Corporation | 721.36 Million USD | 88.573% |
| Ikena Oncology, Inc. | 22.33 Million USD | -269.075% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -3851.726% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | 19.648% |
| Gossamer Bio, Inc. | 249.14 Million USD | 66.914% |
| CohBar, Inc. | 1.03 Million USD | -7875.036% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -671.195% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -332.765% |
| Legend Biotech Corporation | 589.93 Million USD | 86.027% |
| Mural Oncology plc | 37.92 Million USD | -117.341% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 37.85% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -3491.332% |
| Disc Medicine, Inc. | 22.87 Million USD | -260.363% |
| Champions Oncology, Inc. | 28.03 Million USD | -194.036% |
| REGENXBIO Inc. | 262.22 Million USD | 68.564% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -2353.836% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -557.675% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -513.723% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -288.743% |
| Vaxart, Inc. | 34.02 Million USD | -142.272% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -304.296% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -188.915% |
| Cellectis S.A. | 249.57 Million USD | 66.971% |
| Longeveron Inc. | 5.33 Million USD | -1444.557% |
| Repare Therapeutics Inc. | 41.81 Million USD | -97.119% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 96.573% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -36.551% |
| Revolution Medicines, Inc. | 262.39 Million USD | 68.585% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -3812.34% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -855.634% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -598.526% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -487.004% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -3732.311% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 98.399% |
| Denali Therapeutics Inc. | 122.96 Million USD | 32.961% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -1381.304% |
| Veru Inc. | 32.81 Million USD | -151.223% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -1100.073% |
| Cingulate Inc. | 10.36 Million USD | -695.619% |
| Passage Bio, Inc. | 39.26 Million USD | -109.956% |
| Context Therapeutics Inc. | 4.19 Million USD | -1866.57% |
| Exicure, Inc. | 8.54 Million USD | -864.241% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -179.358% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -686.124% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -273.998% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 49.423% |
| Nuvalent, Inc. | 31.82 Million USD | -159.036% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -1195.785% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -30.8% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -357.961% |
| OmniAb, Inc. | 87.4 Million USD | 5.683% |
| Anew Medical, Inc. | 8.24 Million USD | -900.182% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -115.291% |
| Lipocine Inc. | 2.63 Million USD | -3032.394% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -213.768% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -104.996% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -209.412% |
| G1 Therapeutics, Inc. | 86.15 Million USD | 4.319% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -1426.254% |
| Sage Therapeutics, Inc. | 82.74 Million USD | 0.379% |
| Ocugen, Inc. | 23.98 Million USD | -243.714% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -77.631% |
| Q32 Bio Inc. | 233.12 Million USD | 64.64% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -809.254% |
| Alumis Inc. Common Stock | 53.5 Million USD | -54.075% |
| Equillium, Inc. | 27.95 Million USD | -194.856% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 60.099% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -1365.042% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -1244.096% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 47.604% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -18.723% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -726.462% |
| Dominari Holdings Inc. | 4.63 Million USD | -1678.49% |
| Edesa Biotech, Inc. | 1.84 Million USD | -4376.072% |
| vTv Therapeutics Inc. | 29.56 Million USD | -178.801% |
| Bio-Techne Corporation | 744.34 Million USD | 88.925% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 34.628% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 76.069% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -103.162% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -184.674% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | 10.748% |
| Nkarta, Inc. | 105.6 Million USD | 21.938% |
| BioCardia, Inc. | 4.59 Million USD | -1695.926% |
| Iterum Therapeutics plc | 32.66 Million USD | -152.382% |